Eli Lilly (LLY 3.20%) is firing on all cylinders. That's not news to anyone paying close attention to the biotech industry, nor is the company a newcomer to success. The drugmaker's stock has crushed the broader market over the past five years.Here's the million-dollar question, though: Can Eli Lilly keep up the momentum? Past success doesn't guarantee anything, after all. And some investors might fear that they have missed the boat. Perhaps it's too late to invest in Eli Lilly. But is that the case?Let's f ...

智通财经APP获悉，在“减肥神药”Zepbound强势催化之下，美国医药巨头礼来(LLY.US)股价屡创新高之势促使华尔街大行摩根士丹利(Morgan Stanley)的分析师们思考，该医药巨头会否成为“美股七大科技巨头”(Magnificent Seven)之外第一家市值达到1万亿美元的美国医药公司。2023年礼来股价涨幅超60%，自2024年以来礼来股价不断创新高，涨幅已高达35%，截至周五收盘股价为782.06美元。 根据机构计算，随着摩根士丹利的分析师们周五将这家减肥药制药商之一的目标股价上调至华尔街最高水平，这将使该公司的总市值达到约9000亿美元。机构测算数据显示，要达到1万亿美元市值大关，该股必须达到1,053.40美元。 在周五，摩根士丹利分析师特伦斯•弗林(Terence Flynn)领导的分析团队将该机构对于礼来的12个月目标股价从805美元上调至950美元。 “礼来可能将成为全球首只市值1万亿美元的生物医药及制药类股票吗?”摩根士丹利分析师特伦斯•弗林及其同事在给客户的一份报告中表示。“在我们看来可能性很大，我们继续看到进一步上涨的空间。” 该公司股价截至周五收盘上涨3.2%，再度创下 ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned +14.7% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has gained 4.3% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports ...

Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (LLY -0.39%), which won U.S. approval in November for Zepbound, and Novo Nordisk (NVO -0.55%), which markets Ozempic and Wegovy. Lilly's share price has soared more than 115% over the last 12 months, while Novo Nordisk stock is up over 70%. But will these two weight-loss giants continue to dominate over the near term? Not if analysts are right. Move aside, Eli Lilly and Novo Nordisk. Wall Street thinks this stock will be a bigger w ...

Biotech giant Eli Lilly (LLY 0.61%) is firing on all cylinders. The company has scorched the broader market over the past year thanks to its rapidly growing revenue and important clinical and regulatory progress. However, the No. 1 reason Eli Lilly has been performing so well is tirzepatide, its clinical compound known as Mounjaro in the diabetes market, and Zepbound in the anti-obesity space.Eli Lilly recently reported more positive news regarding this medicine. Let's find out what it was and what investor ...

You may not expect a pharmaceutical stock to mimic the behavior of the latest hot growth stock and soar in the triple digits over 12 months. But Eli Lilly (LLY 0.61%) did it, climbing nearly 117% over the past year. This wasn't just a random happening, but instead evidence investors are very excited about what's to come for this pharma giant.Lilly's portfolio is generating double-digit revenue growth, into the billions of dollars. And the products leading this are two that doctors have been prescribing for ...

In science and in life, there's a special prestige that comes with being the first person or group to crack a previously intractable problem by using a cunning approach. Believe it or not, bragging rights matter to massive pharma players like Eli Lilly (LLY 0.61%), too. The question is, should such attainments matter to investors if the financial benefits from them are ambiguous?This isn't just an academic question. A few weeks ago, Lilly showed some proof that one of its clinical programs did what others c ...

In this articleNVONOVO.B-DKLLYInjection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023.Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. But both companies ar ...

Shares of Eli Lilly (LLY 0.62%) rose over 10% this week, according to data from S&P Global Market Intelligence. The drugmaker is soaring due to continued success with its weight loss drugs, which are growing like gangbusters. Revenue growth is accelerating, and the stock is now up over 1,000% in the last 10 years, crushing the returns of the S&P 500 index.Here's why Eli Lilly stock was rising yet again this week. A weight loss revolution?Eli Lilly posted its fourth-quarter 2023 earnings this week. Revenue g ...

INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly. "Through his deep financial knowledge and understanding of the business, industry and stake ...